No dedicated clinical trials have compared denosumab and bisphosphonates for fracture prevention in patients on dialysis.

Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...

US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

January saw almost every major cardiovascular subspecialty represented among our most-clicked stories of the month.

TUESDAY, Jan. 7, 2025 (HealthDay News) -- For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on fractures but an increased risk for ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...

Dr. Reddy's net profit for the third quarter is expected to grow 10% YoY, with revenues likely increasing 13% YoY, based on ...